NextDocs Corporation, a provider of Microsoft SharePoint-based compliance solutions for the life sciences industry, announced the launch of Trial Exchange, its newest product available on the NextDocs platform. Trial Exchange provides a consumer-style interface for investigators and site staff to access and contribute essential documents for clinical trials. As documents are uploaded through Trial Exchange, the documents enter workflows within the existing NextDocs eTMF module.
“NextDocs’ clinical product line is focused on delivering new innovations to the market. eTMF addressed the internal and partner collaboration challenges and now, with Trial Exchange, we’re enabling trial site staff to participate directly in the process,” explained Matt Walz, CTO at NextDocs. “Trial Exchange does not require training. It has a user experience that feels very consumer, but on the back-end, it is enterprise software and integrates seamlessly with eTMF and other clinical systems.”
Trial Exchange aims to address the challenges that life sciences companies face in managing clinical documents. It hopes to allow trial site staff to contribute documents to an established eTMF work stream, receive and complete tasks generated by the sponsor, view document statuses, and retrieve documents on demand. Trial Exchange is designed to reduce the time and cost of trial management, improve collaboration with investigators, and strengthen document security and compliance.
This new clinical portal allows life sciences companies to:
Trial Exchange provides a streamlined interface for investigators that clinical site staff can use with little to no training. Unlike many existing clinical portals, it plugs directly into the eTMF without additional routing, thus applying the Sponsor/CRO quality and document management processes to clincial site documents.
For more information on Trial Exchange or to register for an upcoming demo of our clinical document management solution, visit www.trialexchange.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.